Impact of host responses on control of hepatitis C virus infection in Chinese blood donors

Biochemical and Biophysical Research Communications

Volumn 415, Issue 3, 2011, Pages 503-508

  Li, Tingting ^a   Chen, Zixuan ^a   Zeng, Jinfeng ^b   Zhang, Jingang ^c   Wang, Wenjing ^a   Zhang, Ling ^a   Zheng, Xin ^b   Shuai, Lifang ^d   Klenerman, Paul ^e   Allain, Jean Pierre ^a,f   Li, Chengyao ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Shenzhen Blood Center   (China)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^d Guangzhou Military Centre of Disease Control   (China)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Chinese; HCV; Molecular factors; Spontaneous control

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; VIRUS ANTIBODY; VIRUS RNA;

ADULT; ARTICLE; BLOOD DONOR; CHINA; CHINESE; CONTROLLED STUDY; CORRELATION ANALYSIS; FALSE POSITIVE RESULT; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRAL CLEARANCE; VIRUS LOAD;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD DONORS; CHINA; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERON-ALPHA; INTERFERON-GAMMA; MALE; VIRAL LOAD; YOUNG ADULT;

HEPATITIS C VIRUS;

EID: 82355180859     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.10.102     Document Type: Article

References (27)

1. Kim W.R. Global epidemiology and burden of hepatitis C. Microbes infect. 2002, 4:1219-1225.
2. Micallef J.M., Kaldor J.M., Dore G.J. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J. Viral. Hepat. 2006, 13:34-41.
3. Candotti D., Temple J., Sarkodie F., Allain J.P. Frequent recovery and broad genotype 2 diversity characterize hepatitis C virus infection in Ghana, West Africa. J. Virol. 2003, 77:7914-7923.
4. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., Kidd J., Kidd K., Khakoo S.I., Alexander G., Goedert J.J., Kirk G.D., Donfield S.M., Rosen H.R., Tobler L.H., Busch M.P., McHutchison J.G., Goldstein D.B., Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
5. Pybus O.G., Charleston M.A., Gupta S., Rambaut A., Holmes E.C., Harvey P.H. The epidemic behaviour of the hepatitis C virus. Science 2001, 292:2323-2325.
6. Chen Y.D., Liu M.Y., Yu W.L., Li J.Q., Peng M., Dai Q., Liu X., Zhou Z.Q. Hepatitis C virus infections and genotypes in China. Hepatobiliary Pancreat. Dis. Int. 2002, 1:194-201.
7. Frese M., Pietschmann T., Moradpour D., Haller O., Bartenschlager R. Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J. Gen. Virol. 2001, 82:723-733.
8. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L., Häussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347:975-982.
9. Cacciarelli T.V., Martinez O.M., Gish R.G., Villanueva J.C., Krams S.M. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and post-treatment with interferon alfa. Hepatology 1996, 24:6-9.
10. Li C., Allain J.P. Chimeric monoclonal antibodies to the hypervariable region 1 of Hepatitis C virus. J. Gen. Virol. 2005, 86:1709-1716.
11. Li C., Candotti D., Allain J.P. Production and characterization of monoclonal antibodies specific for a conserved epitope within hepatitis C virus hypervariable region 1. J. Virol. 2001, 75:12412-12420.
12. Wawrzynowicz-Syczewska M., Kubicka J., Lewandowski Z., Boroń-Kaczmarska A., Radkowski M. Natural history of acute symptomatic hepatitis type C. Infection 2004, 32:138-143.
13. Tanaka E., Kiyosawa K. Natural history of acute hepatitis C. J. Gastroenterol. Hepatol. 2000, 15(Suppl.):E97-E104.
14. Semmo N., Barnes E., Taylor C., Kurtz J., Harcourt G., Smith N., Klenerman P. T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors. Lancet 2005, 365:327-329.
15. Takaki A., Wiese M., Maertens G., Depla E., Seifert U., Liebetrau A., Miller J.L., Manns M.P., Rehermann B. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat. Med. 2000, 6:578-582.
16. Murphy E.L., Fang J., Tu Y., Cable R., Hillyer C.D., Sacher R., Triulzi D., Gottschall J.L., Busch M.P. Hepatitis C virus prevalence and clearance among US blood donors, 2006-2007: associations with birth cohort, multiple pregnancies, and body mass index. J. Infect. Dis. 2010, 202:576-584.
17. Tobler L.H., Bahrami S.H., Kaidarova Z., Pitina L., Winkelman V.K., Vanderpool S.K., Guiltinan A.M., Cooper S., Busch M.P., Murphy E.L. A case-control study of factors associated with resolution of hepatitis C viremia in former blood donors (CME). Transfusion 2010, 50:1513-1523.
18. Busch M.P., Glynn S.A., Stramer S.L., Orland J., Murphy E.L., Wright D.J., Kleinman S. Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors. Transfusion 2006, 46:469-475.
19. Zhang M., Rosenberg P.S., Brown D.L., Preiss L., Konkle B.A., Eyster M.E., Goedert J.J. Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. Blood 2006, 107:892-897.
20. Dolganiuc A., Chang S., Kodys K., Mandrekar P., Bakis G., Cormier M., Szabo G. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J. Immunol. 2006, 177:6758-6768.
21. Zhang T., Lin R.T., Li Y., Douglas S.D., Maxcey C., Ho C., La J.P., Wang Y.J., Wan Q., Ho W.Z. Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines. Hepatology 2005, 42:819-827.
22. Frese M., Schwärzle V., Barth K., Krieger N., Lohmann V., Mihm S., Haller O., Bartenschlager R. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002, 35:694-703.
23. Ye L., Wang X., Metzger D.S., Riedel E., Montaner L.J., Ho W. Upregulation of SOCS-3 and PIAS-3 impairs IL-12-mediated interferon-gamma response in CD56 T cells in HCV-infected heroin users. PLoS ONE 2010, 5:e9602.
24. Chuang W.C., Sarkodie F., Brown C.J., Owusu-Ofori S., Brown J., Li C., Navarrete C., Klenerman P., Allain J.P. Protective effect of HLA-B57 on HCV genotype 2 infection in a West African population. J. Med. Virol. 2007, 79:724-733.
25. Amoroso P., Rapicetta M., Tosti M.E., Mele A., Spada E., Buonocore S., Lettieri G., Pierri P., Chionne P., Ciccaglione A.R., Sagliocca L. Correlation between virus genotype and chronicity rate in acute hepatitis C. J. Hepatol. 1998, 28:939-944.
26. Afdhal N.H., McHutchison J.G., Zeuzem S., Mangia A., Pawlotsky J.M., Murray J.S., Shianna K.V., Tanaka Y., Thomas D.L., Booth D.R., Goldstein D.B. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 2011, 53:336-345.
27. Badr G., Bédard N., Abdel-Hakeem M.S., Trautmann L., Willems B., Villeneuve J.P., Haddad E.K., Sékaly R.P., Bruneau J., Shoukry N.H. Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J. Virol. 2008, 82:10017-10031.